The NovaBridge Biosciences (NBP) SEC filings page on Stock Titan provides access to the company’s official disclosures as a foreign private issuer listed on Nasdaq. NovaBridge, formerly known as I-Mab, files reports such as Form 20-F and Form 6-K that describe its financial condition, risk factors, and operational progress as a global biotechnology platform company.
In these filings, NovaBridge outlines its business model, which combines business development and translational clinical development to advance a pipeline led by givastomig, ragistomig, uliledlimab, and VIS-101. Management’s discussion and analysis sections describe how the company allocates resources to oncology and ophthalmology programs, summarizes its collaborations with partners such as ABL Bio, and explains the structure of subsidiaries like Visara within its hub-and-spoke framework.
Investors reviewing NovaBridge’s SEC reports can examine clinical development disclosures for givastomig, including its positioning as a Claudin 18.2 x 4-1BB bispecific antibody in gastric and other gastrointestinal cancers, and for ragistomig as a PD-L1 x 4-1BB bispecific in solid tumors. Filings also discuss rights to uliledlimab outside Greater China and the VIS-101 license and assignment arrangements involving Visara and Everest Medicines.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as segment descriptions, collaboration agreements, share incentive plans, and subsequent events. Users can follow new 6-K submissions for interim updates, and consult annual filings for a more comprehensive view of NovaBridge’s strategy, risk profile, and pipeline.
By using this page, investors and researchers can monitor NovaBridge’s official SEC communications in real time, while AI-generated insights help interpret complex biotech and capital markets information contained in the original documents.
NovaBridge Biosciences director Emmett Cunningham reported an initial holding of employee stock options linked to 120,000 Ordinary Shares. These 2025 Employee Share Options carry an exercise price of $3.2100 per share and expire on February 17, 2036.
The option was granted on February 17, 2026 and vests in three equal annual installments starting on the first anniversary of the grant date. The footnotes state that Ordinary Shares may be represented by ADSs, with 10 ADSs representing 23 Ordinary Shares, and that the underlying share count and exercise price are expressed in terms of ADSs.
NovaBridge Biosciences executive Xu Cong Claire filed an initial ownership report detailing current equity interests in the company. The filing lists several employee share options over Ordinary Shares granted between 2021 and 2024 at exercise prices ranging from $60.7000 to $1.0500, with expirations extending to 2034. It also discloses restricted share units that each represent a right to receive one American Depositary Share, and a direct holding of 288,266 Ordinary Shares. The derivative awards include both fully vested options and grants that vest over time according to specified multi‑year schedules.
NovaBridge Biosciences director Liu Xin filed an initial ownership report on Form 3. This filing establishes Liu Xin as a reporting insider of the company but does not list any stock transactions or detailed holdings. It is a routine compliance step required under insider reporting rules.
NovaBridge Biosciences executive Zhang Adeline Yi, who serves as Global Controller, has filed an initial insider ownership report on Form 3 for the company. The filing does not list any buy, sell, or derivative transactions and shows no reported gifts, tax withholdings, or restructurings.
NovaBridge Biosciences director Woo Ian Ying has filed an initial Form 3 disclosing equity awards tied to the company’s American Depositary Shares (ADSs). The filing lists a 2025 employee share option with an exercise price of 6.13, covering 15,850 underlying Ordinary Shares, and expiring on October 15, 2035. It also reports 17,310 restricted share units (RSUs), each representing a contingent right to receive one ADS, vesting in three equal annual installments on October 15, 2026, 2027 and 2028. The options vest in three equal annual installments beginning on the first anniversary of the October 15, 2025 grant date.
NovaBridge Biosciences director Lenz Robert A. has reported his existing equity awards in the company. He holds a 2025 employee share option covering 19,130 underlying securities with an exercise price of $5.09 per ADS, expiring on August 22, 2035, vesting in three equal annual installments starting on the first anniversary of the August 22, 2025 grant date. He also holds 22,460 restricted share units, each representing a contingent right to receive one ADS, vesting in three equal annual installments on August 22, 2026, 2027 and 2028. These entries reflect compensation-related awards rather than open-market share purchases or sales.
NovaBridge Biosciences director Au Chun Kwok Alan has reported his derivative equity holdings in a new Form 3. He holds a 2024 Employee Share Option covering 114,093 Ordinary Shares at an exercise price of 1.2200 per share, expiring on October 1, 2034, which is fully vested and exercisable.
He also holds a 2025 Employee Share Option covering 34,530 underlying Ordinary Shares at an exercise price of 3.8600, expiring on October 1, 2035, which vests in full on the first anniversary of the October 1, 2025 grant date. Footnotes note that Ordinary Shares may be represented by ADSs, with each 10 ADSs representing 23 Ordinary Shares, and that the underlying amounts and exercise prices are expressed in ADS terms.
NovaBridge Biosciences submitted a Form 144 disclosing a planned sale of Common Stock through Citigroup Global Markets, Inc. on 03/18/2026 tied to Restricted Stock Units Vesting of 10,302 shares. The filing also records a prior sale of 3,431 shares by Dennis Phillip Andrew on 12/18/2025.
NovaBridge Biosciences reports that the FDA has confirmed givastomig’s potential eligibility for an accelerated approval pathway in first-line Her2-, CLDN 18.2+, PD-L1+ gastroesophageal cancer. This decision follows positive Phase 1b data from a combination trial in gastric cancer.
The company plans a registrational Phase 3 trial in combination with immunochemotherapy, targeted to start as early as Q4 2026, using objective response rate as the primary endpoint for accelerated approval. In Phase 1b, givastomig produced a 75% objective response rate across 52 evaluable patients, with 77% at 8 mg/kg and 73% at 12 mg/kg.
Median progression-free survival reached 16.9 months, with an 82% 6‑month landmark PFS rate in 53 evaluable patients, and overall tolerability was described as good without dose-dependent toxicity. Givastomig, a bispecific Claudin 18.2 x 4‑1BB antibody, is positioned as a potential first-in-class and best-in-class therapy in this setting.
NovaBridge Biosciences reported positive Phase 2a results for VIS-101, a dual VEGF-A and ANG-2 inhibitor being developed for wet age-related macular degeneration and other retinal vascular diseases. In 38 patients treated with 3 mg or 6 mg doses, VIS-101 delivered rapid, robust and durable responses.
Patients showed mean best corrected visual acuity gains of more than 10 ETDRS letters and median central subfield thickness reductions of 100–150 µm after three loading injections. Around two thirds of patients were retreatment-free at four months and about half remained retreatment-free at six months, with a favorable safety profile and no dose-limiting toxicity.
The company plans to start a dose-determining Phase 2b study in the second half of 2026 and a global Phase 3 program in 2027. NovaBridge also highlighted a cash balance of $228 million, which it expects will fund operations through 2028 to reach key clinical milestones for VIS-101 and other pipeline assets.